Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients.
- Resource Type
- Article
- Source
- Biomedicines; Jun2023, Vol. 11 Issue 6, p1540, 7p
- Subject
MONOCLONAL antibodies IMMUNOCOMPROMISED patients COVID-19 TREATMENT effectiveness FISHER exact test - Language
- ISSN
- 22279059